Aluminium based adjuvants and a disease hypothesis by Gherardi

https://www.youtube.com/watch?v=Syabv4Vsrpg

 

I have been posting for some time that I believe ME/CFS is really the disease characterised by Prof Gherardi under the name of macrophagic myofasciitis.

The above is an interview with Prof Gherardi on his research and also reveals that his research funding was mysteriously cut off once it became clear that adjuvants based on aluminium caused neurological disease.

 

It is worth remembering that adjuvants can cause disease after a considerable time lag from vaccination

http://www.smartvax.com/images/PDF/adjuvants_autoimm_review_2011.pdf

 

Just from a quick google, it seems that Gherardi is not widely respected, and it seems that there's not good evidence for some of the claims he makes. It also seems that almost all the papers referring to macrophagic myofasciitis are ones that he has helped author.

I'd be cautious with this stuff.

 

It seems more like someone perseverating on the subject of vaccines and their ingredients.

 

https://www.youtube.com/watch?v=vfS38ErqVxY

You could try watching this video. There are now a considerable number of scientists concerned about this matter.

 

https://www.youtube.com/watch?v=zaExaqCv5vo

 

https://www.youtube.com/watch?v=zaExaqCv5vo

 

https://www.youtube.com/watch?v=zaExaqCv5vo

 

And an entire army of paid astroturfers and brigaders to make sure a "quick google" will lead with results that cast doubt/shade.
There is a powerful industry behind masking this issue, so much like with ME, the good research one would like to see just doesn't get done.

It's a terrible shame bc we could be vaccinating ourselves safely and on a sane schedule if the industry hadn't gone rogue.

 

Has he done any reputable research, or just the mouse studies with some methodological issues? It's a bit odd to sell a theory using videos if there's any decent scientific support.

But I'm glad the videos were linked - I went through and down-voted them both.

 

Does he have documentation or other records to prove that is the case, rather than funding being cut off due to poor methodology or other unreliable practices? Researchers usually seem keen to avoid taking the blame when they lose funding, and might have an incentive to blame vague external forces.

 

Do you have details / evidence about who paid who to do what?

 

Today's new word:

 

I am very disappointed with the response from members of this forum.

I came onto this website believing that people here were interested in scientific research and would give it a fair hearing.

This research is not new, research into the adverse effects of aluminium based adjuvants has been going on for years and you only need to google Gherardi, Schoenfeld and Exley to find that out. In fact it has been known or suspected for many years that a number of illnesses are connected to aluminium based adjuvants and these diseases are increasing. - parkinson's multiple sclerosis, lupus ME/CFS, autism. There cannot be a genetic reason for this increase, it has to be environmental.

I have put up the research papers in the past - I thought the videos would be easier for people to understand.

I have a long history of working in the ME world and when I became ill in 1981 ME was not new. I watched it progressively being stigmatised and sidelined by those with the power in government to release research funding.

You have to ask yourself Why?

I believe that government institutions have known or suspected all along that ME/CFS is linked to vaccination and for reasons of public health policy have refused to help those who suffer from ME/CFS or research this illness.

They have already had a long run in denial and abuse of sufferers, and it is time this stopped.

There is now incontrovertable research evidence showing how adjuvants cause disease. This did not exist ten years ago.

It is vital that we, as sufferers who have paid the price for these government policies of denial and neglect, understand what has been done to us and why.

 

Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines
Romain Kroum Gherardi,1,* Housam Eidi,1 Guillemette Crépeaux,1 François Jerome Authier,1 and Josette Cadusseau1

Abstract
Aluminum oxyhydroxide (alum) is a crystalline compound widely used as an immunological adjuvant of vaccines. Concerns linked to the use of alum particles emerged following recognition of their causative role in the so-called macrophagic myofasciitis (MMF) lesion detected in patients with myalgic encephalomyelitis/chronic fatigue/syndrome. MMF revealed an unexpectedly long-lasting biopersistence of alum within immune cells in presumably susceptible individuals, stressing the previous fundamental misconception of its biodisposition. We previously showed that poorly biodegradable aluminum-coated particles injected into muscle are promptly phagocytosed in muscle and the draining lymph nodes, and can disseminate within phagocytic cells throughout the body and slowly accumulate in brain. This strongly suggests that long-term adjuvant biopersistence within phagocytic cells is a prerequisite for slow brain translocation and delayed neurotoxicity. The understanding of basic mechanisms of particle biopersistence and brain translocation represents a major health challenge, since it could help to define susceptibility factors to develop chronic neurotoxic damage. Biopersistence of alum may be linked to its lysosome-destabilizing effect, which is likely due to direct crystal-induced rupture of phagolysosomal membranes. Macrophages that continuously perceive foreign particles in their cytosol will likely reiterate, with variable interindividual efficiency, a dedicated form of autophagy (xenophagy) until they dispose of alien materials. Successful compartmentalization of particles within double membrane autophagosomes and subsequent fusion with repaired and re-acidified lysosomes will expose alum to lysosomal acidic pH, the sole factor that can solubilize alum particles. Brain translocation of alum particles is linked to a Trojan horse mechanism previously described for infectious particles (HIV, HCV), that obeys to CCL2, signaling the major inflammatory monocyte chemoattractant.

Billions of humans have been vaccinated and marked regression or eradication of several severe infectious diseases was observed. Nowadays, the potential applications of vaccines extend far beyond prevention of infectious diseases, and vaccination is considered to be a most promising weapon against a variety of different conditions. Vaccine safety has been regarded as excellent at the level of the population (1), but adverse effects have also been reported (2).

Concerns about the use of aluminum adjuvants have emerged following (i) recognition of their role at the origin of the so-called macrophagic myofasciitis (MMF) lesion in 2001 (3, 4), which revealed fundamental misconception of their adjuvant effect and pointed out their unexpectedly long-lasting biopersistence (4); and (ii) demonstration of their apparent capacity to migrate in lymphoid organs and then disseminate throughout the body within monocyte-lineage cells and progressively accumulate in the brain (5).

The present paper will review these emerging characteristics of alum adjuvant particles that raise concerns about innocuity of this widely used compound.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318414/

 

ASIA' - autoimmune/inflammatory syndrome induced by adjuvants.
Shoenfeld Y1, Agmon-Levin N.
Author information

Abstract
The role of various environmental factors in the pathogenesis of immune mediated diseases is well established. Of which, factors entailing an immune adjuvant activity such as infectious agents, silicone, aluminium salts and others were associated with defined and non-defined immune mediated diseases both in animal models and in humans. In recent years, four conditions: siliconosis, the Gulf war syndrome (GWS), the macrophagic myofasciitis syndrome (MMF) and post-vaccination phenomena were linked with previous exposure to an adjuvant. Furthermore, these four diseases share a similar complex of signs and symptoms which further support a common denominator.Thus, we review herein the current data regarding the role of adjuvants in the pathogenesis of immune mediated diseases as well as the amassed data regarding each of these four conditions. Relating to the current knowledge we would like to suggest to include these comparable conditions under a common syndrome entitled ASIA, "Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants".

https://www.ncbi.nlm.nih.gov/pubmed/20708902

 

Why? Forum members have considered what you have said and engaged in a discussion about it. Why does critical reading and thinking disappoint you?

 

Aluminium in brain tissue in autism

• Matthew Molda,
• Dorcas Umarb,
• Andrew Kingc,
• Christopher Exleya,

Open Access
Abstract
Autism spectrum disorder is a neurodevelopmental disorder of unknown aetiology. It is suggested to involve both genetic susceptibility and environmental factors including in the latter environmental toxins. Human exposure to the environmental toxin aluminium has been linked, if tentatively, to autism spectrum disorder. Herein we have used transversely heated graphite furnace atomic absorption spectrometry to measure, for the first time, the aluminium content of brain tissue from donors with a diagnosis of autism. We have also used an aluminium-selective fluor to identify aluminium in brain tissue using fluorescence microscopy. The aluminium content of brain tissue in autism was consistently high. The mean (standard deviation) aluminium content across all 5 individuals for each lobe were 3.82(5.42), 2.30(2.00), 2.79(4.05) and 3.82(5.17) μg/g dry wt. for the occipital, frontal, temporal and parietal lobes respectively. These are some of the highest values for aluminium in human brain tissue yet recorded and one has to question why, for example, the aluminium content of the occipital lobe of a 15 year old boy would be 8.74 (11.59) μg/g dry wt.? Aluminium-selective fluorescence microscopy was used to identify aluminium in brain tissue in 10 donors. While aluminium was imaged associated with neurones it appeared to be present intracellularly in microglia-like cells and other inflammatory non-neuronal cells in the meninges, vasculature, grey and white matter. The pre-eminence of intracellular aluminium associated with non-neuronal cells was a standout observation in autism brain tissue and may offer clues as to both the origin of the brain aluminium as well as a putative role in autism spectrum disorder.

http://www.sciencedirect.com/science/article/pii/S0946672X17308763

 

https://www.nature.com/articles/srep31578

Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations

• Matthew Mold
• , Emma Shardlow
• & Christopher Exley

Aluminium adjuvants remain the most widely used and effective adjuvants in vaccination and immunotherapy. Herein, the particle size distribution (PSD) of aluminium oxyhydroxide and aluminium hydroxyphosphate adjuvants was elucidated in attempt to correlate these properties with the biological responses observed post vaccination. Heightened solubility and potentially the generation of Al3+in the lysosomal environment were positively correlated with an increase in cell mortality in vitro, potentially generating a greater inflammatory response at the site of simulated injection. The cellular uptake of aluminium based adjuvants (ABAs) used in clinically approved vaccinations are compared to a commonly used experimental ABA, in an in vitro THP-1 cell model. Using lumogallion as a direct-fluorescent molecular probe for aluminium, complemented with transmission electron microscopy provides further insight into the morphology of internalised particulates, driven by the physicochemical variations of the ABAs investigated. We demonstrate that not all aluminium adjuvants are equal neither in terms of their physical properties nor their biological reactivity and potential toxicities both at the injection site and beyond. High loading of aluminium oxyhydroxide in the cytoplasm of THP-1 cells without immediate cytotoxicity might predispose this form of aluminium adjuvant to its subsequent transport throughout the body including access to the brain.